BD Diagnostics receives FDA approval for imaging system that enhances detection of cervical cancer
Researchers provide insight into how Toxoplasma gondii, a common parasite of people and other animals, triggers an immune response in its host. The report will appear online on January 19th in The Journal of Experimental Medicine . A strong immune response spares T. gondii -infected hosts from deadly infection-an event that may also benefit the
Full Post: Insight into how Toxoplasma gondii triggers immune response in its host
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) has announced that it received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the BD FocalPoint(TM) GS Imaging System.
This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath(TM) Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.
“The launch of the BD FocalPoint(TM) GS System represents a key milestone in our effort to expand BD’s presence in cancer diagnostics,” said Vincent A. Forlenza, BD Executive Vice President. “It is the first in a series of innovative products aimed at improving the detection and clinical management of cancer, resulting from our TriPath acquisition.”
Despite significant improvements in cervical cancer screening over the past 40 years, nearly 4,000 women die from the disease each year in the United States, and costs to treat the disease exceed $2 billion annually. The key to detecting cervical cancer early is regular Pap testing. However, limitations exist with current technologies. Approximately one-third of Pap smear false negatives can be attributed to screening and interpretive errors in which abnormal cells are incorrectly classified.
The new BD FocalPoint(TM) GS Imaging System seeks to address this problem by offering laboratories key advantages over current cervical cancer imaging systems. Its state-of-the-art guided screening (GS) technology helps rapidly relocate the fields of view that the system has identified as the most likely to contain cells of interest.
“Our clinical trial results give us confidence that the BD FocalPoint(TM) GS Imaging System will provide cytology labs with the advanced tool they need to improve cervical cancer detection and enhance their productivity,” said Wayne Brinster, Vice President and General Manager, BD Diagnostics - TriPath. “It demonstrates BD’s commitment to providing innovative, world-class products and services for the oncology market that help improve patient outcomes by offering clinicians better tools to detect and manage disease.”
The use of human papillomavirus (HPV) DNA testing as an initial screening step followed by triage with a standard Pap test (cytology) and repeat HPV DNA testing may increase the accuracy of cervical cancer screening, according to a study in the Jan. 13 online issue of the Journal of the National Cancer Institute. Compared to
Full Post: HPV testing followed by cytology and repeat HPV testing may improve cervical cancer screening
As a part of National Cervical Health Awareness Month, Acting Secretary of Health Everette James has reminded women of the importance of cervical cancer prevention and the need for pap tests. “Every January as we begin a new year, we want to remind all Pennsylvanians to do what they can to improve their overall health,”
Full Post: Women reminded yearly examinations best way to prevent cervical cancer
Women living in the most deprived areas of England are nearly twice as likely to be diagnosed with cervical cancer than their affluent counterparts - according to a report presented by national cancer director Professor Mike Richards at the Britain Against Cancer conference today (Tuesday). The report, published by the National Cancer Intelligence Network (NCIN),
Full Post: Living in deprived areas of England doubles cervical cancer risk
SpectraScience, Inc. has announced that it has been awarded U.S. Patent number 7,469,160 for its methods and apparatus for evaluating image focus. Jim Hitchin, SpectraScience’s CEO, commented, “This patent is another important addition to our expanding intellectual property portfolio.” The invention provides methods of focusing an instrument for the acquisition of optical data from a
Full Post: SpectraScience awarded U.S. patent for methods and apparatus for evaluating image focus
As testing for high-risk types of the human papillomavirus (HPV) emerges as the gold standard in cervical cancer prevention, scientists are already researching how to determine even more precisely who is most likely to develop the disease and thus are in need of more immediate intervention. Speaking at the EUROGIN (European Research Organization on Genital
Full Post: Researchers say identifying women with HPV types 16, 18 and 45 could improve early intervention to stop cervical cancer